Your browser doesn't support javascript.
Elevated serum IgA following vaccination against SARS-CoV-2 in a cohort of high-risk first responders.
Montague, Brian T; Wipperman, Matthew F; Chio, Erica; Crow, Rowena; Hooper, Andrea T; O'Brien, Meagan P; Simões, Eric A F.
  • Montague BT; University of Colorado School of Medicine, Aurora, CO, USA. brian.montague@cuanschutz.edu.
  • Wipperman MF; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Chio E; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Crow R; University of Colorado School of Medicine, Aurora, CO, USA.
  • Hooper AT; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • O'Brien MP; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Simões EAF; University of Colorado School of Medicine, Aurora, CO, USA. eric.simoes@cuanschutz.edu.
Sci Rep ; 12(1): 14932, 2022 Sep 02.
Article in English | MEDLINE | ID: covidwho-2008320
ABSTRACT
IgA plays an important early neutralizing role after SARS-CoV-2 infection. Systemically administered vaccines typically produce an IgM/IgG predominant response. We evaluated the serum anti-spike (anti-S) IgG, anti-nucleocapsid (anti-N) IgG and anti-S IgA response following vaccination against SARS-CoV-2 in a cohort of first-responders. Among the 378 completely vaccinated participants, 98% were positive for anti-S IgG and 96% were positive for anti-S IgA. Nine percent were positive for anti-N IgG suggesting prior exposure to SARS-CoV-2. No statistically significant difference was seen in IgA response based on prior evidence infection (p = 0.18). Ninety-eight of those receiving the Moderna vaccine (98%) were positive for anti-S IgA as compared to 91% of those who received the Pfizer vaccine (p = 0.0009). The high proportion of participants observed to have a positive anti-S IgA response after vaccination suggests that the vaccines elicit a systemic response characterized by elevated levels of both IgG and IgA.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Emergency Responders / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-19095-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Emergency Responders / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-19095-7